Op 23/06/2025 verdedigt Milton Antwi zijn proefschrift getiteld "“Therapeutic potential of PPARα-ERRα crosstalk in mitigating metabolic dysfunction-associated steatotic liver disease progression”
Locatie en tijdstip: June 23 at 5 p.m. (CEST) at FSVM I Research Building, Jozef Schell Seminar Room, Technologiepark-Zwijnaarde 71, 9052 Zwijnaarde.
Promotoren:
· Prof. Dr. Karolien De Bosscher
· Dr. Sander Lefere
· Prof. Dr. Lindsey Devisscher
Jury leden:
· Prof. Dr. Bart Dermaut (voorzitter)
· Prof. Dr. Vanessa Dubois (secretaris)
· Dr. Charlotte Verroken
· Dr. Jolien Vandewalle
· Prof. Dr. Mathieu Vinken
· Prof. Dr. Wim Vanden Berghe
· Prof. Dr. Sven Francque
Meer informatie:
Metabolic dysfunction-associated steatotic liver disease (MASLD), linked to obesity and cardiometabolic disorders, poses significant health risks, potentially progressing to severe conditions like fibrosis, cirrhosis, and hepatocellular carcinoma. Current treatments are limited, underscoring the urgent need for innovative therapeutic strategies. In this doctoral research, we investigated the combination of PPARα and ERRα ligands in liver cell lines and mice models that reflect human MASLD, uncovering their synergistic beneficial effects to inhibit MASLD disease progression. The combination improved body weight, liver morphology, reduced inflammation and fibrosis, and prevented tumor formation. Additionally, we investigated the impact of these ligand combinations on liver sinusoidal endothelial cells (LSECs), which play a crucial role in liver health but are impaired during MASLD progression. We demonstrated that combined PPARα–ERRα ligands significantly improved LSEC morphology, reducing endothelial markers and adhesion molecules during MASLD disease progression. Overall, the findings of this doctoral thesis highlight promising pathways for future MASLD therapeutic interventions.